February 6, 2017
Ablynx submits its thrombosis antibody to EMA
Ablynx has applied its caplacizumab to European Medicines Agency for approval to use it for a form of blod clotting disorder.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
February 6, 2017
TiGenix to present results of Crohn`s disease drug trial at ECCO
TiGenix will present results from its Phase III trial of Crohn`s disease drug, named Cx601, at the upcoming 12th Annual Congress of the…
February 6, 2017
Portola nets $150M deal with HealthCare Royalty Partners
Portola Pharmaceuticals has signed a $150 million royalty deal with HealthCare Royalty Partners (HCR).
February 4, 2017
World Cancer Day: Worldwide cases of cancer predicted to reach 21.7 million by 2030
Coordinated by Union for International Cancer Control (UICC), World Cancer Day is this year taking place under the tagline ‘We can. I can.’ and explores how everyone – as a collective or as individuals – can do their part to reduce the global burden of cancer.
February 3, 2017
Sobi negotiates sale of its Partner Products business area
Swedish Orphan Biovitrum is negotiating with a private equity firm regarding a possible sale of its Partner Products business area excluding Kineret and Orfadin.
February 3, 2017
Allergan expects annual dividend rise
Allergan’s boss Brent Saunders said that the company plans to increase dividend on an annual basis over time.
February 3, 2017
DBV Technologies completes P II study of milk-induced EoE treatment
DBV Technologies has completed a Phase IIA investigator-initiated clinical trial of Viaskin Milk for the treatment of milk-induced Eosinophilic Esophagitis (EoE) in children ages 4-17 has been completed.
February 3, 2017
FDA approves Bristol-Myers’s Opdivo for urothelial bladder cancer
U.S. Food and Drug Administration (FDA) has approved Bristol-Myers’s Opdivo injection, for treatment of urothelial carcinoma (mUC).
February 2, 2017
Eli Lilly keeps Alimta patent in Japan for now, new challenges on the way
Japan IP High Court confirmed validity of Eli Lilly’s Alimta vitamin regimen patents, and has invalidated trials initiated by Sawai regarding Lilly’s vitamin regimen patents for Alimta.
February 2, 2017
MENA biologics industry first ever Biopharma Conference at CPhI Istanbul 2017
With the goal of developing Turkey as an R&D and technology hub, the Government has put place a number of measures to stimulate expansion of biotechnology and biopharmaceutical activities.